Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Below Two Hundred Day Moving Average - Here's Why

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $27.65 and traded as low as $18.98. Capricor Therapeutics shares last traded at $19.79, with a volume of 2,254,084 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Roth Capital reaffirmed a "buy" rating and set a $38.00 price target on shares of Capricor Therapeutics in a research report on Friday, May 15th. LADENBURG THALM/SH SH raised shares of Capricor Therapeutics to a "strong-buy" rating in a research note on Thursday, June 25th. Finally, HC Wainwright reiterated a "buy" rating and issued a $60.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $53.67.

Capricor Therapeutics Trading Up 1.5%

The stock's 50 day moving average price is $25.90 and its 200 day moving average price is $27.65. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -8.53 and a beta of 0.42.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, research analysts expect that Capricor Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of the business's stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00. Following the transaction, the chief financial officer owned 8,223 shares of the company's stock, valued at $260,669.10. The trade was a 75.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 50,000 shares of company stock worth $1,551,658. 9.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Capricor Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. KBC Group NV bought a new stake in Capricor Therapeutics during the first quarter worth $44,000. ACT Capital Management LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter valued at about $43,000. Allworth Financial LP increased its stake in shares of Capricor Therapeutics by 5,021.5% during the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company's stock worth $96,000 after purchasing an additional 3,264 shares during the last quarter. State of Wyoming raised its holdings in shares of Capricor Therapeutics by 76.0% in the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company's stock valued at $128,000 after purchasing an additional 1,913 shares during the period. Finally, Royal Bank of Canada lifted its stake in Capricor Therapeutics by 12.4% in the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company's stock valued at $146,000 after purchasing an additional 557 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.